Caduet (Amlodipine/Atorvastatin )

Verify with FDA CVM →

62 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
62
Total Reports
23
Deaths Reported
3710.0%
Death Rate

Active Ingredients

Caduet (Amlodipine/Atorvastatin )

Administration Routes

UnknownOralOther

Species Affected

Cat 31
Dog 30
Unknown 1

Most Affected Breeds

Domestic Shorthair 25
Retriever - Labrador 6
Poodle (unspecified) 3
Spaniel (unspecified) 2
Maltese 2
Shih Tzu 2
Terrier - Jack Russell 1
Unknown 1
Bichon Frise 1
Cat (unknown) 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 21
Death by euthanasia 17
Anorexia 14
Elevated blood urea nitrogen (BUN) 13
Vomiting 11
Other abnormal test result NOS 10
Diarrhoea 9
Anaemia NOS 9
Hypertension 8
Elevated creatinine 8
Leucocytosis NOS 8
Seizure NOS 7

Outcome Breakdown

Ongoing
23 (37.7%)
Euthanized
17 (27.9%)
Recovered/Normal
8 (13.1%)
Outcome Unknown
7 (11.5%)
Died
6 (9.8%)

Data Summary

Metric Value
Total adverse event reports 62
Reports involving death 23
Case-fatality rate (reported events) 3710.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Caduet (Amlodipine/Atorvastatin ) Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 62 adverse event reports referencing Caduet (Amlodipine/Atorvastatin ), including 23 reports in which the animal died — a 3710.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Caduet (Amlodipine/Atorvastatin ). Reported administration routes include Unknown, Oral, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Caduet (Amlodipine/Atorvastatin ) reports are Cat (31 reports), Dog (30 reports), Unknown (1 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (25), Retriever - Labrador (6), Poodle (unspecified) (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Caduet (Amlodipine/Atorvastatin ) are Lethargy (see also Central nervous system depression in 'Neurological') (21), Death by euthanasia (17), Anorexia (14), Elevated blood urea nitrogen (BUN) (13). Of the 61 reports with a coded outcome, Ongoing is the leading category at 37.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Caduet (Amlodipine/Atorvastatin ).

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial